Physician profile
Philip G Liu
NPI 1316055122
$1,820.65
in general payments reported to CMS, 2019-2025
16 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.08 · 2020: $185 · 2021: $259 · 2022: $307 · 2023: $343 · 2024: $342 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $776.46 | 2019-2025 | Dupixent |
| Optinose US, INC. | $285.07 | 2020-2025 | |
| Glaxosmithkline, LLC. | $174.60 | 2022-2025 | Nucala |
| Intersect Ent, INC. | $171.44 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $124.82 | 2022-2024 | Orladeyo |
| Aerin Medical INC. | $62.87 | 2022 | |
| Stryker Corporation | $37.27 | 2019-2020 | |
| Vapotherm INC | $33.82 | 2021 | |
| Acclarent, INC | $28.69 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $26.74 | 2021 | |
| Phadia US INC. | $19.72 | 2025 | Immunocap |
| Medtronic, INC. | $19.06 | 2021 | |
| Phathom Pharmaceuticals, INC. | $16.14 | 2025 | Voquezna |
| Medtronic USA, INC. | $15.86 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.01 | 2025 | Tezspire |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.